Pfizer Newsroom

Pfizer (PFE) Gets a Buy From Cantor Fitzgerald

TipRanksJul 1 20:27 ET

Pfizer Analyst Ratings

BenzingaJul 1 11:21 ET

Pfizer Analyst Ratings

BenzingaJun 26 12:11 ET

Pfizer Analyst Ratings

BenzingaJun 17 13:34 ET

Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target

BenzingaJun 17 13:33 ET

Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained

TipRanksMay 30 23:00 ET

Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement

TipRanksMay 30 22:26 ET

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

TipRanksMay 28 01:16 ET

Wells Fargo Remains a Hold on Pfizer (PFE)

TipRanksMay 22 05:55 ET

DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating

MT NewswiresMay 20 07:26 ET

Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating

MT NewswiresMay 13 05:58 ET

Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)

TipRanksMay 2 16:21 ET

Pfizer Analyst Ratings

BenzingaMay 2 10:28 ET

Pfizer Exceeds Q1 Expectations With Strong Earnings and Raises 2024 Guidance: A Buy Rating by Evan Seigerman

TipRanksMay 2 07:40 ET

Leerink Adjusts Price Target on Pfizer to $29 From $27

MT NewswiresMay 2 06:47 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)

TipRanksMay 2 06:35 ET

Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating

MT NewswiresMay 2 06:20 ET

Pfizer (PFE) Receives a Hold From Barclays

TipRanksMay 2 04:00 ET

Buy Rating Affirmed for Pfizer Amid Strong Q1 Performance and Strategic Cost Savings

TipRanksMay 2 01:20 ET

Jefferies Remains a Buy on Pfizer (PFE)

TipRanksMay 1 16:45 ET